Journal
BIOMATERIALS
Volume 34, Issue 21, Pages 5344-5358Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2013.03.068
Keywords
pH-responsive; Nanoparticle; Cyclodextrin; Drug delivery; Tumor therapy; Nanomedicine
Funding
- National Natural Science Foundation of China [81271695, 21004077]
Ask authors/readers for more resources
Engineering of pH-responsive nanoplatforms can be facilely achieved from acetalated alpha-cyclodextrin materials. The hydrolysis period of nanoparticles can be precisely tailored by using materials with various acetal types that can be easily controlled by acetalation time. These nanomaterials with pH-modulated hydrolysis and pH-triggered drug delivery capability show good biocompatibility in vitro and in vivo. Incorporation of anticancer drug paclitaxel (FIX) into newly developed pH-sensitive nanosystems leads to nanotherapeutics with significantly improved cytotoxic activity against various tumor cells. Importantly, thus formulated nanomedicines can reverse the multidrug resistance of PTX-resistant cancer cells. In vivo antitumor studies also reveal the superior of pH-sensitive nanosystems over pristine PTX and pH-insensitive PLGA nanoformulations. Moreover, comparison with other two acid-labile materials evidenced the advantages of cyclodextrin-based nanovehicles with respect to drug loading capacity, in vitro and in vivo activity as well as alleviated adverse effects. These pH-responsive nanoparticles may serve as new generation nanocarriers for drug delivery. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available